Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRAS^G12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumors.

ABSTRACT:

Background

Public neoantigens, including KRAS, TP53, and PIK3CA mutations, which are shared across various tumor types, have demonstrated significant immunogenicity and offer great promise for cancer immunotherapy. Clinical trials targeting these public neoantigens have yielded encouraging results, including tumor regression and prolonged relapse-free survival. This study evaluates the human leukocyte antigen (HLA) binding properties of T-cell epitopes derived from these public neoantigens to identify optimal T-cell target and further develops T-cell receptor (TCR)-based therapeutics.

Methods

The binding properties of public neoantigens to HLA-I molecules were evaluated using peptide-HLA binding affinity and stability assays. Naive T-cell repertoires were used to expand and

SUBMITTER: Shen M 

PROVIDER: S-EPMC12278171 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature